Vidac Pharma is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its breakthrough new technology, which corrects a common characteristic of all cancer cells, harbors the promise of a fundamentally new way of treating cancer, and become a routine part of oncology combination therapies.
The company, established in 2012, is led by Prof Max Herzberg, one of the founding fathers of Israel’s life science industry. Vidac Pharma is developing medicines to help cancer patients by reversing the abnormal metabolism of cancer cells, and halting cancer cell proliferation. The company boasts a strong leadership team, with many decades of experience in science and management between them, backed by an international group of scientific advisors of the highest standing.
With a strong IP portfolio, Vidac’s main asset is in clinical trial for two indications, while a powerful new drug candidate with a possible wide application in solid tumors is in preclinical trial.
Vidac’s lead drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors, has already proven to be a more powerful candidate in ongoing preclinical trials.
Vidac is listed on the Hamburg and Stuttgart stock exchanges (T9G).